Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336178 | 0.86 | PDE10A (0.42) | KCNH2PDE10APIK3CAMTOR | |
| SCHEMBL15850834 | 0.80 | KCNH2 (0.41) | KCNH2PDE10A | |
| SCHEMBL15850865 | 0.75 | KCNH2 (0.39) | KCNH2PDE10A | |
| SCHEMBL20753951 | 0.73 | PDE10A (0.42) | KCNH2PDE10APIK3CAMTOR | |
| SCHEMBL21321489 | 0.71 | PDE10A (0.42) | KCNH2PDE10A | |
| SCHEMBL3405904 | 0.69 | KCNH2 (0.39) | KCNH2PDE10A | |
| SCHEMBL3405907 | 0.69 | KCNH2 (0.39) | KCNH2PDE10A | |
| SCHEMBL1432243 | 0.69 | P2RX3 (0.43) | KCNH2PDE10A | |
| SCHEMBL15850814 | 0.68 | CYP1A2 (0.41) | KCNH2PDE10A | |
| SCHEMBL334845 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| EP-2300476-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306089-A1 | COMPOUNDS | SDHA, NQO1, SDHB | KCNH2 2851/4885PDE10A 627/4885PIK3CA 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.